What is the future of CCR5 antagonists in rheumatoid arthritis?

被引:8
|
作者
Takeuchi, Tsutomu [1 ]
Kameda, Hideto [1 ]
机构
[1] Keio Univ, Div Rheumatol, Dept Internal Med, Sch Med,Shinjyu Ku, Toky 1608582, Japan
关键词
DOUBLE-BLIND; CHEMOKINE; RECEPTORS; BLOCKADE; TRIAL;
D O I
10.1186/ar3775
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fleishaker and colleagues reported on a double-blind placebo controlled clinical trial of a C-C chemokine-receptor type 5 (CCR5) antagonist, maraviroc, in rheumatoid arthritis (RA) patients with inadequate response to methotrexate, showing that it was ineffective. Two additional CCR5 antagonists, SCH351125 and AZD5672, also failed to demonstrate clinical efficacy. In addition, CCR5-blocking antibodies could not inhibit synovial fluid-induced monocyte chemotaxis. Thus, CCR5 appears not to be a desirable target in RA treatment. Given the multiple functions of CCR5, redundancies in the chemokine system, and patient selection in the trial, we overview the recent understanding for chemokine receptor blockade in the treatment of RA
引用
收藏
页数:2
相关论文
共 50 条
  • [21] CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study
    Luis Rodríguez-Rodríguez
    Carlos González-Juanatey
    Mercedes García-Bermúdez
    Tomas R Vázquez-Rodríguez
    Jose A Miranda-Filloy
    Benjamin Fernández-Gutiérrez
    Javier Llorca
    Javier Martin
    Miguel A González-Gay
    Arthritis Research & Therapy, 13
  • [22] The chemoattraction of lymphocytes by rheumatoid arthritis - synovial fluid is not dependent on the chemokine receptor CCR5
    Santiago, B
    Galindo, M
    Rivero, M
    Brehmer, MT
    Mateo, I
    Pablos, JL
    RHEUMATOLOGY INTERNATIONAL, 2002, 22 (03) : 107 - 111
  • [23] CCR5Δ32 and the genetic susceptibility to rheumatoid arthritis in admixed populations: a multicentre study
    Toson, Bruno
    dos Santos, Eduardo Jose
    Adelino, Jose Eduardo
    Sandrin-Garcia, Paula
    Crovella, Sergio
    Louzada-Junior, Paulo
    Ribeiro Oliveira, Rene Donizete
    Rosa Aquino Pedroza, Larysse Santa
    Lobato Cunha Sauma, Maria de Fatima
    Silva de Lima, Clayton Pereira
    Barbosa, Fabiola Brasil
    Brenol, Claiton Viegas
    Xavier, Ricardo Machado
    Bogo Chies, Jose Artur
    Veit, Tiago Degani
    RHEUMATOLOGY, 2017, 56 (03) : 495 - 497
  • [24] CCR5 Antagonists: a New Class of Antiretrovirals.
    Peytavin, Gilles
    Calvez, Vincent
    Katlama, Christine
    THERAPIE, 2009, 64 (01): : 9 - 16
  • [25] CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study
    Rodriguez-Rodriguez, Luis
    Gonzalez-Juanatey, Carlos
    Garcia-Bermudez, Mercedes
    Vazquez-Rodriguez, Tomas R.
    Miranda-Filloy, Jose A.
    Fernandez-Gutierrez, Benjamin
    Llorca, Javier
    Martin, Javier
    Gonzalez-Gay, Miguel A.
    ARTHRITIS RESEARCH & THERAPY, 2011, 13 (04)
  • [26] The chemoattraction of lymphocytes by rheumatoid arthritis – synovial fluid is not dependent on the chemokine receptor CCR5
    B. Santiago
    M. Galindo
    M. Rivero
    M. Brehmer
    I. Mateo
    J. Pablos
    Rheumatology International, 2002, 22 : 107 - 111
  • [27] Small Molecule Antagonists of the Chemokine Receptor CCR5
    Lemoine, Remy C.
    Wanner, Jutta
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2010, 10 (13) : 1299 - 1338
  • [28] Isolation and structure of antagonists of chemokine receptor (CCR5)
    Jayasuriya, H
    Herath, KB
    Ondeyka, JG
    Polishook, JD
    Bills, GF
    Dombrowski, AW
    Springer, MS
    Siciliano, S
    Malkowitz, L
    Sanchez, M
    Guan, ZQ
    Tiwari, S
    Stevenson, DW
    Borris, RP
    Singh, SB
    JOURNAL OF NATURAL PRODUCTS, 2004, 67 (06): : 1036 - 1038
  • [29] Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker
    Arribas Lopez, Jose R.
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2008, 26 : 23 - 27
  • [30] CCR5 antagonists as anti-HIV agents
    不详
    DRUG DISCOVERY TODAY, 2001, 6 (14) : 747 - 747